The Pharmacy Technician Certification Board (PTCB) announced the launch of a new certificate in MTM for pharmacy technicians.

This year has seen the approval of 2 new biosimilar drugs, including the first biosimilar to earn FDA’s “interchangeable” designation. Byooviz (ranibizumab-nuna) is biosimilar to Lucentis (ranibizumab), a drug for neovascular (wet) age-related macular degeneration (nAMD). Semglee (insulin glargine-yfgn), the first such drug to earn the “interchangeable” distinction, is biosimilar to Lantus (insulin glargine) for diabetes.

New research from CDC, published in the December issue of Pediatrics, shows that the virus that causes mumps continues to circulate in the United States, primarily infecting people vaccinated against it, including children.

According to CDC, people most often cite pain management as their reason for using medical cannabis in the United States. But according to a new clinical practice guideline published by Busse and colleagues in the September 2021 issue of BMJ, there is weak evidence to support the use of non-inhaled medical cannabis or cannabinoids for chronic pain. The recommendation is based on a robust analysis of results from 32 randomized controlled clinical trials.

Results of a Phase IV study published in The Lancet find no safety concerns with coadministration of the COVID-19 vaccine and the influenza vaccine.